

Amendments to the Claims:

Claims 24-27, 29-36, 38, 40, 42, and 44 are canceled, without prejudice or disclaimer.

Claim 28 is currently amended.

This amendment adds, changes and/or deletes claims in this application. A detailed listing of all claims that are, or were, in the application, irrespective of whether the claim(s) remain under examination in the application, are presented. The text of all claims presently under examination is presented below in the listing of claims, and all claims are presented with an appropriate defined status identifier.

Detailed and Complete Listing of Claims:

1. (Withdrawn) Use of an oligonucleotide as a primer for synthesizing the polynucleotide comprising the nucleotide sequence set forth in any one of SEQ ID NOs: 1-5547 and SEQ ID NOs: 16111-16164, or the complementary strand thereof, wherein said oligonucleotide is complementary to said polynucleotide or the complementary strand thereof and comprises at least 15 nucleotides.
- 2-5. (Canceled).
6. (Withdrawn) A substantially pure protein encoded by polynucleotide of claim 4.
7. (Withdrawn) A partial peptide of the protein of claim 6.
8. (Canceled).
9. (Withdrawn) A substantially pure protein encoded by the polynucleotide of claim 8.
10. (Withdrawn) An antibody against the protein or peptide of any one of claims 6, 7, and 9.
- 11-13. (Canceled).
14. (Withdrawn) A method for producing the protein or peptide of any one of claims 6, 7, and 9, comprising culturing the transformant of claim 13 and recovering the expression product.
15. (Canceled).
16. (Withdrawn) Use of the oligonucleotide of claim 15 as a primer for synthesizing a polynucleotide.
17. (Withdrawn) Use of the oligonucleotide of claim 15 as a probe for detecting a gene.

18. (Canceled).
19. (Withdrawn) A method for synthesizing a polynucleotide, the method comprising:
- a) synthesizing a complementary strand using a cDNA library as a template, and using the primer set of claim 2 or 3, or the primer of claim 16; and
 - b) recovering the synthesized product.
20. (Withdrawn) The method of claim 19, wherein the cDNA library is obtainable by oligo-capping method.
21. (Withdrawn) The method of claim 19, wherein the complementary strand is obtainable by PCR.
22. (Withdrawn) A method for detecting the polynucleotide of claim 8, the method comprising:
- a) incubating a target polynucleotide with the oligonucleotide of claim 15 under the conditions where hybridization occurs, and
 - b) detecting the hybridization of the target polynucleotide with the oligonucleotide of claim 15.
23. (Withdrawn) A database of polynucleotides and/or proteins, the database comprising information on at least one sequence selected from the nucleotide sequences of claim 8 (a) and/or the amino acid sequences of claim 8 (b), or a medium on which the database is stored.
- 24-27. (Canceled).
28. (Currently Amended) An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising ~~a coding region of~~ the nucleotide sequence ~~set forth in~~ of positions 416 to 1174 of SEQ ID NO. 10847; and
 - (b) a polynucleotide comprising a nucleotide sequence encoding ~~a protein comprising the full-~~

length amino acid sequence set forth in SEQ ID NO: 10848;

~~(c) a polynucleotide comprising a nucleotide sequence encoding a protein comprising an amino acid sequence selected from the amino acid sequences of (b), in which up to 5% of the amino acids are substituted, deleted, inserted, and/or added, wherein said protein comprises a secretory or membrane protein associated with diabetes;~~

~~(d) a polynucleotide that hybridizes under highly stringent conditions with a polynucleotide comprising a nucleotide sequence selected from the nucleotide sequence of (a), and that comprises a nucleotide sequence encoding a protein comprising a secretory or membrane protein associated with diabetes;~~

~~(e) a polynucleotide comprising a nucleotide sequence with at least 95% identity to the nucleotide sequence of (a), wherein said polynucleotide encodes a secretory or membrane protein associated with diabetes.~~

29-36. (Canceled).

37. (Previously Presented) A vector comprising the polynucleotide of claim 28.

38. (Canceled).

39. (Previously Presented) A transformant carrying the polynucleotide of claim 28.

40. (Canceled).

41. (Previously Presented) A transformant carrying the vector of claim 37.

42. (Canceled).

43. (Previously Presented) A transformant expressively carrying the polynucleotide of claim 28.

44. (Canceled).

45. (Previously Presented) A transformant expressively carrying the vector of claim 37.